Editor-In-Chief
Current
Feb 2017 - Present
AeroLeads people directory · profile
John Rex Email & Phone Number
Chief Medical Officer, F2G, Ltd; Editor-in-Chief, AMR.Solutions; Operating Partner, Advent Life Sciences
at
AMR.Solutions
1 work email found
@rexweb.org
6 phones found area 978, 202, and 425
LinkedIn matched
✓ Verified August 2026
4 data sources
Profile completeness 100%
Current company
Role
Chief Medical Officer, F2G, Ltd; Editor-in-Chief, AMR.Solutions; Operating Partner, Advent Life Sciences
Location
Wellesley Hills, Massachusetts, United States
Who is John Rex? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
John Rex is listed as Chief Medical Officer, F2G, Ltd; Editor-in-Chief, AMR.Solutions; Operating Partner, Advent Life Sciences at AMR.Solutions, based in Wellesley Hills, Massachusetts, United States. AeroLeads shows a work email signal at rexweb.org, phone signal with area code 978, 202, 425, and a matched LinkedIn profile for John Rex.
John Rex previously worked as Editor-In-Chief at Amr.Solutions and Chief Medical Officer at F2G. John Rex holds Md, Medicine from Baylor College Of Medicine.
Company email context
Email format at AMR.Solutions
This section adds company-level context without repeating John Rex's masked contact details.
jrex@rexweb.org
76% confidence
AeroLeads found 1 current-domain work email signal for John Rex. Compare company email patterns before reaching out.
Profile bio
About John Rex
I am a physician and drug developer with more than 30 years of development and policy experience focused on antimicrobial agents. My development experience includes moving compound opportunities from early preclinical development through all later stages of development in the context of (a) academic training and faculty positions (NIH, Bethesda, MD; Univ. of Texas Medical School-Houston), (b) an internal role at a multinational pharmaceutical firm (AstraZeneca Pharmaceuticals), (c) board-level roles in two biotech firms (F2G Ltd, Adenium Biotech ApS, and (d) an operating partner role with a venture capital investment group (Advent Life Sciences). In parallel and via multiple cross-industry initiatives, I have actively driven changes to the global regulatory and policy environment for antimicrobial agents. I am one of the two Industry-based cofounders of the Innovative Medicines Initiative’s New Drugs for Bad Bugs (ND4BB) program bringing Industry and Academic collaborators together on a range of antibiotic discovery and development projects. I currently also serve on the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria and am an Expert-in-Resident at Wellcome Trust, London, UK.
Listed skills include Clinical Research, Drug Discovery, Biochemistry, Microbiology, and 24 others.
Current workplace
John Rex's current company
Company context helps verify the profile and gives searchers a useful next step.
20 roles
John Rex work experience
A career timeline built from the work history available for this profile.
Chief Medical Officer
CurrentBased in Manchester, UK, F2G Ltd is dedicated to discovery and development of clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. As Chief Medical Officer, I actively lead the clinical development program.
Jun 2021 - Present
Chief Medical Officer And Director
Based in Manchester, UK, F2G Ltd is dedicated to discovery and development of clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. As Chief Medical Officer and Director, I actively lead the clinical development program and work as part of the Board of Directors on long-term company strategy.
Nov 2016 - Jun 2021
Non-Executive Director
Based in Manchester, UK, F2G Ltd is dedicated to discovery and development of clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. At F2G, I both work with the Board on long-term company strategy and I also actively direct F2G’s scientific agenda via membership in the Board’s science committee.
Sep 2012 - Oct 2016
Consultant And Operating Partner
CurrentAdvent Life Sciences is an investor in F2G, Ltd.
Nov 2015 - Present
Adjunct Professor Of Medicine, University Of Texas Medical School-Houston
Current
Jan 2003 - Present
Professor Of Medicine, University Of Texas Medical School-Houston
Assistant Professor (July 1992 to August 1996), Associate Professor (September 1996 to August 2001), Professor (September 2001 to December 2002)
Jul 1992 - Dec 2002
Expert-In-Residence
I provided strategic guidance to Wellcome Trust on its Drug-Resistant Infection initiatives.
Sep 2014 - Dec 2019
Member, Seeding Drug Discovery Committee
Jan 2011 - Dec 2016
Non-Executive Director
Adenium Biotech is a Danish biopharmaceutical company spun out from Novozymes A/S in 2011. Adenium focuses on the development and commercialization of novel antibiotics for the treatment of multi-drug resistant bacterial infections.
Nov 2015 - Sep 2019
Member, Presidential Advisory Council, Action Plan For Combating Antimicrobial Resistant Bacteria
The Advisory Council will provide advice, information, and recommendations to the Secretary of DHHS regarding programs and policies intended to: (1) Preserve the effectiveness of antibiotics by optimizing their use; (2) Advance research to develop improved methods for combating antibiotic resistance and conducting antibiotic stewardship; (3) Strengthen surveillance of antibiotic-resistant bacterial infections; (4) Prevent the transmission of antibiotic-resistant bacterial infections;Advance the development of rapid point-of-care and agricultural diagnostics; (5) Further research on new treatments for bacterial infections; (6) Develop alternatives to antibiotics for agricultural purposes; (7) Maximize the dissemination of up-to-date information on the appropriate and proper use of antibiotics to the general public and human and animal healthcare providers; and (8) Improve international coordination of efforts to combat antibiotic resistance.
Sep 2015 - Dec 2018
Chief Strategy Officer
Carb-X
CARB-X (www.carb-x.org) is a public-private partnership providing non-equity, non-dilutive finance in support of pre-clinical development of antibacterial products. Over an initial 5-year funding cycle, CARB-X will seek to accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre (UK). As Chief Strategy Officer, I worked with the Executive Director to design the overall portfolio strategy for this project.
Jul 2016 - Sep 2017
Senior Vp And Chief Strategy Officer, Infection Business Unit
The AstraZeneca Infection Business Unit is a global leader in developing novel antibacterial therapies. As Chief Strategy Officer, I sought new licensing opportunities for the Business Unit, provided strategic guidance to the Business Unit, and worked to shape relevant global regulatory and payor policies.
Nov 2015 - Oct 2016
Senior Vp And Head Of Infection, Global Medicines Development
Jun 2012 - Oct 2015
Vice President Clinical Infection
Jan 2003 - May 2012
Member, Nominating Committee
Apr 2013 - Mar 2016
Vice Chair, Consensus Committee On Microbiology
Jan 2013 - Dec 2015
Chair, Consensus Committee On Microbiology
Jan 2009 - Dec 2012
Industry Representative, Anti-Infective Drugs Advisory Committee (Aidac)
Nov 2007 - Oct 2011
Editor, Antimicrobial Agents & Chemotherapy
Jul 2000 - Jun 2010
2 education records
John Rex education
Md, Medicine
Baylor College Of Medicine
Ba, Biochemistry
Rice University
FAQ
Frequently asked questions about John Rex
Quick answers generated from the profile data available on this page.
What company does John Rex work for?
John Rex works for AMR.Solutions.
What is John Rex's role at AMR.Solutions?
John Rex is listed as Chief Medical Officer, F2G, Ltd; Editor-in-Chief, AMR.Solutions; Operating Partner, Advent Life Sciences at AMR.Solutions.
What is John Rex's email address?
AeroLeads has found 1 work email signal at @rexweb.org for John Rex at AMR.Solutions.
What is John Rex's phone number?
AeroLeads has found 6 phone signal(s) with area code 978, 202, 425 for John Rex at AMR.Solutions.
Where is John Rex based?
John Rex is based in Wellesley Hills, Massachusetts, United States while working with AMR.Solutions.
What companies has John Rex worked for?
John Rex has worked for Amr.Solutions, F2G, Advent Life Sciences Llp, The University Of Texas Health Science Center At Houston, and Wellcome Trust.
How can I contact John Rex?
You can use AeroLeads to view verified contact signals for John Rex at AMR.Solutions, including work email, phone, and LinkedIn data when available.
What schools did John Rex attend?
John Rex holds Md, Medicine from Baylor College Of Medicine.
What skills is John Rex known for?
John Rex is listed with skills including Clinical Research, Drug Discovery, Biochemistry, Microbiology, Infectious Diseases, Biotechnology, Healthcare, and Clinical Trials.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial